Most microbiota-support approaches used during or after antibiotic exposure rely on live probiotics, which can have variable colonization success and pose additional safety challenges in sensitive populations and manufacturing constraints. This project advances an alternative, more controllable strategy: using defined postbiotics that can be formulated like conventional supplements and are less likely to interfere with natural microbiota re-establishment.
Scientifically, the work links maternal antibiotic exposure, microbiota-related metabolic changes, and long-term offspring behavioral outcomes within one integrated preclinical framework, supported by behavioral, microbiota, metabolomic, and transcriptomic readouts. The results provide early proof that specific metabolites can modulate later-life behavior and brain molecular signatures following prenatal antibiotic exposure.
Expected impacts and key needs for further uptake
If translated successfully, a metabolite-based supplement could provide a low-risk, shelf-stable, and scalable add-on to standard antibiotic therapy in pregnancy, with the long-term goal of supporting healthier neurodevelopment and reducing later behavioral dysregulation in childhood and throughout life. Beyond this specific indication, the approach could create a broader blueprint for developing postbiotic interventions targeted to critical windows in early life.
Key next steps to enable uptake include: selecting the most scalable metabolite(s) (including alternatives within the same pathway if needed), optimizing dose/ratio and delivery format to achieve reliable exposure levels, confirming stability in a capsule or beverage-compatible formulation, repeating efficacy testing with the final formulation in a powered preclinical study, and completing early safety and tolerability work in a clinical setting. In parallel, early dialogue with regulators is needed to clarify the most appropriate product category and allowable claims, followed by first-in-human studies to confirm exposure and tolerability and to prepare for clinical proof-of-concept.
